Currently out of the existing stock ratings of Jason Zemansky, 32 are a BUY (56.14%), 24 are a HOLD (42.11%), 1 are a SELL (1.75%).

Jason Zemansky

Work Performance Price Targets & Ratings Chart

Analyst Jason Zemansky, currently employed at BAML, carries an average stock price target met ratio of 45.24% that have a potential upside of 11.03% achieved within 65 days.

Jason Zemansky’s has documented 110 price targets and ratings displayed on 14 stocks. The coverage is on Healthcare, Financial Services sectors.

Most recent stock forecast was given on RCKT, Rocket Pharmaceuticals at 30-Mar-2026.

Wall Street Analyst Jason Zemansky

Analyst best performing recommendations are on MDGL (MADRIGAL PHARMACEUTICALS).
The best stock recommendation documented was for INSM (INSMED) at 10/27/2025. The price target of $187 was fulfilled within 3 days with a profit of $22.98 (14.01%) receiving and performance score of 46.7.

Average potential price target upside

of $24.3 (37.77%) on ALVR (ALLOVIR ).
of $15.52 (38.42%) on INSM (INSMED).
of $7.49 (16.72%) on CYTK (CYTOKINETICS).

ALLK Allakos CYTK Cytokinetics ESPR Esperion Therapeutics INSM Insmed HOWL Werewolf Therapeutics RCUS Arcus Biosciences ALVR Allovir KURA Kura Oncology SNDX Syndax Pharmaceuticals RCKT Rocket Pharmaceuticals KROS Keros Therapeutics AKRO Akero Therapeutics ALL The Allstate MDGL Madrigal Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jonathan Wolleben (JMP)